It has been 10 years since GMFH was launched with the aim of disseminating the latest gut microbiome research to the lay public, healthcare professionals and scientists alike. In this article, members of the GMFH board of experts share their pick of the most significant advances in the field, outlining their clinical impact and implications for further research.

Clostridioides difficile infection is a common cause of diarrhea in both the hospital and community settings, with C. difficile recurrence one of the most challenging outcomes to address. This article focuses on the factors that predict long-term complications of C. difficile infection and what can be done in clinical practice to minimize them (Part 5).

November, Clostridioides difficile infection awareness month

11 Nov 2022

by Konstantina Zafeiropoulou

Just one month before friends and families gather around the Christmas table, November is here to bring awareness around Clostridioides difficile infection, and the importance of microbiota-derived treatments. With this post, all of us in GMFH aim to highlight the importance of protecting ourselves and families and stopping the spread of this potentially deadly infection.

Bacterial extracellular vesicles: future postbiotics?

18 Oct 2022

by Konstantina Zafeiropoulou

Research into microbial extracellular vesicles has progressed significantly over several decades. Following up on the 1989 breakthrough that bacterial extracellular vesicles contain genetic information, and the recent ISAPP definition on postbiotics, current research suggests bacterial extracellular vesicles derived from probiotic bacteria may be the postbiotics of the future with potential health benefits.

Inflammation has been involved in the onset of chronic diseases. Probiotics emerge as a potential dietary tool for managing those conditions, partly through their role in immune system modulation and the anti-inflammatory response. Find out what is known about the anti-inflammatory effects of probiotics and their potential applications at the bedside.

Bacteria and fungi in the human gut microbiota may contribute to the underlying mechanisms of IBS, which means the latter can be explored as a potential target for IBS. This article explores what is known about the role of the gut microbiome and yeast probiotics in irritable bowel syndrome.

Correcting the altered gut microbiome is an important goal in Clostridioides difficile management, but the matter is not addressed by mainstream treatments with antibiotics. This article focuses on where fecal microbiota transplantation and investigational microbiota-based therapeutics stand for C. difficile infection (Part 3)

While celiac disease affects predominantly the small intestine, the contribution of the small intestinal microbiota has been largely understudied. New findings characterize the duodenal microbiota in patients with active celiac disease and explores its functional relevance.